You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Iomab-ACT: A phase I/II study of 131-I apamistamab targeted lymphodepletion followed by CD19-targeted CAR T-cell therapy for patients with relapsed or refractory B-ALL or DLBCL

    SBC: Actinium Pharmaceuticals, Inc.            Topic: 102

    ABSTRACT Despite treatment advances, the prognosis of adult patients with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) and R/R diffuse large B-cell lymphoma (DLBCL) remains poor. Autologous T- cells modified to express a CD19-targeted chimeric antigen receptor (CAR T-cells) produce durable responses in subgroups of these patients, which has led to FDA approval of two su ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Controlled-release Microbeads to Replace Growth Factors in Fetal Bovine Serum

    SBC: STEM CULTURES LLC            Topic: 400

    Scientific Abstract: The frequent use of fetal bovine serum (FBS) to support cell cultures is challenged by lot-to-lot variability, supply constraints, pathogen contaminants and ethical questions. These issues have increased significance due to the burgeoning use of FBS in cell research and therapy development. FBS has been used for over a century to culture cells, but with the need to define cult ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Improved Treatment of Colorectal Cancer with CF10

    SBC: Deep Creek Pharma, LLC            Topic: 102

    PROJECT SUMMARY Decades of modulating the anti-cancer activity of fluoropyrimidine drugs (FPs) thru schedule optimization, biochemical modulation, and drug combinations have provided a significant, but limited, survival advantage for treating colorectal cancer (CRC) patients with locally advanced or metastatic disease (mCRC). However, outcomes remain poor for patients with mCRC and since targeted ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  4. CN-105 Improves Functional Outcome After Intracranial Hemorrhage

    SBC: AegisCN LLC            Topic: 106

    Annually, approximately 100,000 patients in the USA suffer from intracerebral hemorrhage (ICH), which is associated with high mortality rates and poor long-term cognitive and physical recovery. At present, no pharmacological therapies have been demonstrated to improve functional outcomes after ICH. However, we have successfully demonstrated that CN-105, a pentapeptide derived from the receptor bin ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  5. The Assessment of Smart Phone Everyday Tasks (ASSET): A new IADL test for early AD

    SBC: RIP ROAD, INC.            Topic: NIA

    Project SummaryImpairment in instrumental activities of daily living (IADL) is a hallmark of Alzheimer’s disease (AD) dementia and a major source of patient and caregiver burden. Similarly to cognitive changes in AD, subtle difficulties in IADL may begin even before the stage of amnestic mild cognitive impairment (MCI). Recently, greater emphasis has been placed on preclinical AD, which consists ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  6. ARRAY: A novel polymeric mesh for prophylactic antibiotic protection of cardiac implantable electronic devices

    SBC: 21MedTech LLC            Topic: NHLBI

    PROJECT SUMMARY 21MedTech, LLC is developing the ARRAYTM antibiotic-loaded envelope to address the need for novel methods to tackle rising rates of infections associated with cardiovascular implantable electronic devices (CIEDs). There were 1.5 million CIEDs implanted in 2011 and that number continues to grow. Between 1% and 4% of implantations result in infection, which have potential for severe ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Novel recombinant sensors to study histone ubiquitin signaling

    SBC: Epicypher, Inc.            Topic: 400

    PROJECT SUMMARYMonoubiquitination (Ub) of histones is an important post-translational modification (PTM) that regulates multiple DNA-related processes including DNA replication, transcription, and repair. Aberrant regulation of histone Ub is strongly linked to the pathogenesis of diverse diseases, including cancer, aging, and inflammation. However, the ability to map the distribution and dynamics ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  8. A Disease-Modifying Protein Therapeutic for the Treatment of COPD

    SBC: VERRA THERAPEUTICS LLC            Topic: NHLBI

    PROJECT SUMMARY Chronic Obstructive Pulmonary Disease (COPD) is the third leading cause of death worldwide at 3.23 million (2019), while nearly 400 million suffer its effects. COPD is a heterogeneous, multi-phenotypic disease with lung damage derived from smoking, vaping, cooking, forest fires, pollution, chemical exposure, and numerous occupational hazards (e.g., 1st responders, military, agricul ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Development of ultra-efficient antibodies for single cell mapping applications

    SBC: Epicypher, Inc.            Topic: NIAID

    PROJECT SUMMARYHistone post-translational modifications (PTMs) are some of the most widely studied epigenomic factors, and alterations in histone PTM abundance / distribution have been implicated in numerous disease etiologies. Epigenomic mapping of histone PTMs in limited cell populations or single cells (SCs) would provide the opportunity to study the epigenetic landscape of rare and heterogenou ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Development of a Molecular Diagnostic to Identify Dangerous Intracranial Aneurysms

    SBC: NEUROVASCULAR DIAGNOSTICS, INC.            Topic: 103

    Project SummaryIntracranial aneurysm (IA) rupture is the primary cause of non-traumatic subarachnoid hemorrhage, a catastrophic event that carries high rates of mortality (rt50%) and permanent disability (rt50% among survivors). When an unruptured IA is discovered, clinicians face the difficult decision of whether or not it should be treated. Since rupture rates are low (risk of rupture ~ 0.5-1% p ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government